HebeCell and Logomix partner to develop PSC-NK cells
14 Aug 2023
Gene TherapyCell Therapy
Preview
Source: Pharmaceutical Technology
Preview
Source: Pharmaceutical Technology
Biotechnology company HebeCell has entered a strategic collaboration with synthetic biology company Logomix to research and develop gene-edited natural killer (NK) cells.
The companies will also work on discovering genetic alterations that could produce next-generation designer NK cells.
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - AlloRx Stem Cell therapy GlobalData
Preview
Source: Pharmaceutical Technology
ReportsCells Expressing Neural Cell Adhesion Molecule 1 (Antigen Recognized By Monoclonal Antibody 5.1H1... GlobalData
View allCompanies IntelligencePSC Corporation LtdNK Co LtdLogoMix IncHebeCell CorpView all
By merging a pluripotent stem cell (PSC)-based platform with genome-editing expertise, the companies will expand and expedite new development to check for de novo genetic alterations that improve the protoNK cells’ persistence and efficacy against cancers.
HebeCell CEO John Lu stated: “We know our protoNK cells are strong cytotoxic cells. Our goal is to make PSC-derived protoNK more efficacious in vivo.
“This collaboration expands our efforts to develop unique NK cell therapies, and has the potential to create something new and never seen before in the NK therapeutic field.”
Established in 2016, HebeCell focuses on the development of NK cell therapeutics, leveraging its 3D PSC platform.
The off-the-shelf ProtoNK cell products treat cancer, viral infections and autoimmune conditions.
“Because our technology allows Mb-scale and scarless modifications, [when] applied to any sequences at either or both alleles it is an ideal tool to create a source of allogeneic cell therapy with desired gene edits.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.